Ibuprofen enhances TRAIL-induced apoptosis through DR5 upregulation

Oncology Reports

Volumn 30, Issue 5, 2013, Pages 2379-2384

  Todo, Momoko ^a   Horinaka, Mano ^a   Tomosugi, Mitsuhiro ^a   Tanaka, Ryoichi ^a   Ikawa, Haruna ^a   Sowa, Yoshihiro ^a   Ishikawa, Hideki ^a   Fujiwara, Hitoshi ^a   Otsuji, Eigo ^a   Sakai, Toshiyuki ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Apoptosis; DR5; Ibuprofen; TRAIL

Indexed keywords

CASPASE; DEATH RECEPTOR 5; IBUPROFEN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; COLON CANCER; CONTROLLED STUDY; DRUG EFFICACY; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

APOPTOSIS; COLONIC NEOPLASMS; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HUMANS; IBUPROFEN; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; TNF-RELATED APOPTOSIS-INDUCING LIGAND; UP-REGULATION;

EID: 84885046114     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2713     Document Type: Article

References (44)

1. Weitz J, Koch M, Debus J, Höhler T, Galle PR and Büchler MW: Colorectal cancer. Lancet 365: 153-165, 2005.
2. Brasky TM, Bonner MR, Moysich KB, et al: Non-steroidal anti-inflammatory drugs (NSAIDs) and breast cancer risk: differences by molecular subtype. Cancer Causes Control 22: 965-975, 2011.
3. Walter RB, Milano F, Brasky TM and White E: Long-term use of acetaminophen, aspirin, and other nonsteroidal anti-inflammatory drugs and risk of hematologic malignancies: results from the prospective Vitamins and Lifestyle (VITAL) study. J Clin Oncol 29: 2424-2431, 2011.
4. Thun MJ, Namboodiri MM and Heath CW Jr: Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325: 1593-1596, 1991.
5. Baron JA, Cole BF, Sandler RS, et al: A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 348: 891-899, 2003.
6. Rothwell PM, Wilson M, Elwin CE, et al: Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 376: 1741-1750, 2010.
7. Rothwell PM, Wilson M, Price JF, et al: Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 379: 1591-1601, 2012.
8. Ishikawa H, Nakamura T, Kawano A, Gondo N and Sakai T: Chemoprevention of colorectal cancer in Japan: a brief introduction to current clinical trials. J Gastroenterol 44: 77-81, 2009.
9. Ishikawa H, Wakabayashi K, Suzuki S, et al: Preventive effects of low-dose aspirin on colorectal adenoma growth in patients with familial adenomatous polyposis: double-blind, randomized clinical trial. Cancer Med 2: 50-56, 2013.
10. Antithrombotic Trialists' Collaboration: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324: 71-86, 2002.
11. Adams SS, McCullough KF and Nicholson JS: The pharmacological properties of ibuprofen, an anti-inflammatory, analgesic and antipyretic agent. Arch Int Pharmacodyn Ther 178: 115-129, 1969.
12. Chan AT, Ogino S and Fuchs CS: Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 356: 2131-2142, 2007.
13. Ogino S, Kirkner GJ, Nosho K, et al: Cyclooxygenase-2 expression is an independent predictor of poor prognosis in colon cancer. Clin Cancer Res 14: 8221-8227, 2008.
14. Kawamori T, Rao CV, Seibert K and Reddy BS: Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 58: 409-412, 1998.
15. Solomon SD, McMurray JJ, Pfeffer MA, et al: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352: 1071-1080, 2005.
16. Baron JA, Sandler RS, Bresalier RS, et al: A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 131: 1674-1682, 2006.
17. Harris RE, Beebe-Donk J and Alshafie GA: Similar reductions in the risk of human colon cancer by selective and nonselective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer 14: 237, 2008.
18. Schönthal AH, Chen TC, Hofman FM, et al: Celecoxib analogs that lack COX-2 inhibitory function: preclinical development of novel anticancer drugs. Expert Opin Investig Drugs 17: 197-208, 2008.
19. Bonelli P, Tuccillo FM, Calemma R, et al: Changes in the gene expression profile of gastric cancer cells in response to ibuprofen: a gene pathway analysis. Pharmacogenomics J 11: 412-428, 2011.
20. Greenspan EJ, Madigan JP, Boardman LA and Rosenberg DW: Ibuprofen inhibits activation of nuclear β-catenin in human colon adenomas and induces the phosphorylation of GSK-3β. Cancer Prev Res 4: 161-171, 2011.
21. Harris RE, Beebe-Donk J, Doss H and Burr Doss D: Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: A critical review of non-selective COX-2 blockade (Review). Oncol Rep 13: 559-583, 2005.
22. Taniguchi H, Horinaka M, Yoshida T, et al: Targeting the glyoxalase pathway enhances TRAIL efficacy in cancer cells by downregulating the expression of antiapoptotic molecules. Mol Cancer Ther 11: 2294-2300, 2012.
23. Taniguchi H, Yoshida T, Horinaka M, et al: Baicalein overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance via two different cell-specific pathways in cancer cells but not in normal cells. Cancer Res 68: 8918-8927, 2008.
24. Yoshida T, Maoka T, Das SK, et al: Halocynthiaxanthin and peridinin sensitize colon cancer cell lines to tumor necrosis factor-related apoptosis-inducing ligand. Mol Cancer Res 5: 615-625, 2007.
25. Horinaka M, Yoshida T, Shiraishi T, et al: The dietary flavonoid apigenin sensitizes malignant tumor cells to tumor necrosis factor-related apoptosis-inducing ligand. Mol Cancer Ther 5: 945-951, 2006.
26. Walczak H, Miller RE, Ariail K, et al: Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5: 157-163, 1993.
27. Ashkenazi A, Pai RC, Fong S, et al: Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104: 155-162, 1999.
28. Fesik SW: Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 5: 876-885, 2005.
29. Soria JC, Smit E, Khayat D, et al: Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer. J Clin Oncol 28: 1527-1533, 2010.
30. Leong S, Cohen RB, Gustafson DL, et al: Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study. J Clin Oncol 27: 4413-4421, 2009.
31. Zerafa N, Westwood JA, Cretney E, et al: Cutting edge: TRAIL deficiency accelerates hematological malignancies. J Immunol 175: 5586-5590, 2005.
32. Nakata S, Yoshida T, Horinaka M, Shiraishi T, Wakada M and Sakai T: Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells. Oncogene 23: 6261-6271, 2004.
33. Kim KM, Song JJ, An JY, Kwon YT and Lee YJ: Pretreatment of acetylsalicylic acid promotes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by down-regulating BCL-2 gene expression. J Biol Chem 49: 41047-41056, 2005.
34. Braun FK, Al-Yacoub N, Plötz M, Möbs M, Sterry W and Eberle J: Nonsteroidal anti-inflammatory drugs induce apoptosis in cutaneous T-cell lymphoma cells and enhance their sensitivity for TNF-related apoptosis-inducing ligand. J Invest Dermatol 132: 429-439, 2012.
35. Huang Y, He Q, Hillman MJ, Rong R and Sheikh MS: Sulindac sulfide-induced apoptosis involves death receptor 5 and the caspase 8-dependent pathway in human colon and prostate cancer cells. Cancer Res 61: 6918-6924, 2001.
36. Sinicrope FA and Penington RC: Sulindac sulfide-induced apoptosis is enhanced by a small-molecule Bcl-2 inhibitor and by TRAIL in human colon cancer cells overexpressing Bcl-2. Mol Cancer Ther 4: 1475-1483, 2005.
37. Heijink DM, Jalving M, Oosterhuis D, et al: TNF-related apoptosis-inducing ligand cooperates with NSAIDs via activated Wnt signalling in (pre)malignant colon cells. J Pathol 223: 378-389, 2011.
38. Ricchi P, Zarrilli R, Di Palma A and Acquaviva AM: Nonsteroidal anti-inflammatory drugs in colorectal cancer: from prevention to therapy. Br J Cancer 88: 803-807, 2003.
39. Sheng H, Shao J, Kirkland SC, et al: Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest 99: 2254-2259, 1997.
40. Bjarnason I: Gastrointestinal safety of NSAIDs and over-the-counter analgesics. Int J Clin Pract (Suppl) 178: 37-42, 2013.
41. Schnitzer TJ, Burmester GR, Mysler E, et al: Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 364: 665-674, 2004.
42. Lugardon S, Lapeyre-Mestre M and Montastruc JL: Upper gastrointestinal adverse drug reactions and cyclo-oxygenase-2 inhibitors (celecoxib and rofecoxib): a case/non-case study from the French Pharmacovigilance Database. Eur J Clin Pharmacol 60: 673-677, 2004.
43. Van GE, Jones JK, Moore N, Parc JM, Wall R and Schneid H: A large simple clinical trial prototype for assessment of OTC drug effects using patient-reported data. Pharmacoepidemiol Drug Saf 14: 249-255, 2005.
44. Horinaka M, Yoshida T, Kishi A, et al: Lactobacillus strains induce TRAIL production and facilitate natural killer activity against cancer cells. FEBS Lett 584: 577-582, 2010.